NO301018B1 - Tverrbundne nitrogeninneholdende vinylkopolymerer, fremgangsmåte for fremstilling av dem samt anvendelse av slike forbindelser - Google Patents
Tverrbundne nitrogeninneholdende vinylkopolymerer, fremgangsmåte for fremstilling av dem samt anvendelse av slike forbindelser Download PDFInfo
- Publication number
- NO301018B1 NO301018B1 NO932635A NO932635A NO301018B1 NO 301018 B1 NO301018 B1 NO 301018B1 NO 932635 A NO932635 A NO 932635A NO 932635 A NO932635 A NO 932635A NO 301018 B1 NO301018 B1 NO 301018B1
- Authority
- NO
- Norway
- Prior art keywords
- stands
- residue
- formula
- carbon atoms
- integer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 10
- 229920006163 vinyl copolymer Polymers 0.000 title claims abstract description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- -1 phenoxy- Chemical class 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 238000007334 copolymerization reaction Methods 0.000 claims description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004380 Cholic acid Substances 0.000 claims description 2
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 2
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- 229960002471 cholic acid Drugs 0.000 claims description 2
- 235000019416 cholic acid Nutrition 0.000 claims description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 2
- 229940099347 glycocholic acid Drugs 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-O hydron;pyrimidine Chemical compound C1=CN=C[NH+]=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-O 0.000 claims description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000000969 carrier Substances 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 14
- 239000003613 bile acid Substances 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 5
- 229920001268 Cholestyramine Polymers 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SAWCWRKKWROPRB-UHFFFAOYSA-N 1,1-dibromohexane Chemical compound CCCCCC(Br)Br SAWCWRKKWROPRB-UHFFFAOYSA-N 0.000 description 3
- 229920002911 Colestipol Polymers 0.000 description 3
- 239000003524 antilipemic agent Substances 0.000 description 3
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 3
- 229960002604 colestipol Drugs 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 3
- CYIGRWUIQAVBFG-UHFFFAOYSA-N 1,2-bis(2-ethenoxyethoxy)ethane Chemical compound C=COCCOCCOCCOC=C CYIGRWUIQAVBFG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003312 cholesterol blood level Effects 0.000 description 2
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical group NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000834 vinyl ether Drugs 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 description 1
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical group C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 1
- HBAQUFNXVAMKSZ-UHFFFAOYSA-N 2,3,4-triethylbenzoic acid Chemical group CCC1=CC=C(C(O)=O)C(CC)=C1CC HBAQUFNXVAMKSZ-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- BYKZJCGUBSQXLZ-UHFFFAOYSA-N [C].C=1C=COC=1 Chemical compound [C].C=1C=COC=1 BYKZJCGUBSQXLZ-UHFFFAOYSA-N 0.000 description 1
- RPBWZBPLNQWXMX-UHFFFAOYSA-N [C].N1=CC=CC2=CC=CC=C21 Chemical compound [C].N1=CC=CC2=CC=CC=C21 RPBWZBPLNQWXMX-UHFFFAOYSA-N 0.000 description 1
- YAKMXMGGCREWKW-UHFFFAOYSA-N [C].N1=CNC2=C1C=CC=C2 Chemical compound [C].N1=CNC2=C1C=CC=C2 YAKMXMGGCREWKW-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 description 1
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F259/00—Macromolecular compounds obtained by polymerising monomers on to polymers of halogen containing monomers as defined in group C08F14/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/12—Hydrolysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2810/00—Chemical modification of a polymer
- C08F2810/20—Chemical modification of a polymer leading to a crosslinking, either explicitly or inherently
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Tires In General (AREA)
- Cell Separators (AREA)
- Developing Agents For Electrophotography (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4224110 | 1992-07-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO932635D0 NO932635D0 (no) | 1993-07-21 |
NO932635L NO932635L (no) | 1994-01-24 |
NO301018B1 true NO301018B1 (no) | 1997-09-01 |
Family
ID=6463789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO932635A NO301018B1 (no) | 1992-07-22 | 1993-07-21 | Tverrbundne nitrogeninneholdende vinylkopolymerer, fremgangsmåte for fremstilling av dem samt anvendelse av slike forbindelser |
Country Status (16)
Country | Link |
---|---|
US (2) | US5428112A (fr) |
EP (1) | EP0580079B1 (fr) |
JP (1) | JPH06157671A (fr) |
KR (1) | KR940005692A (fr) |
AT (1) | ATE146193T1 (fr) |
AU (1) | AU659562B2 (fr) |
CA (1) | CA2101010A1 (fr) |
DE (1) | DE59304725D1 (fr) |
DK (1) | DK0580079T3 (fr) |
ES (1) | ES2096150T3 (fr) |
FI (1) | FI933274A (fr) |
GR (1) | GR3022135T3 (fr) |
IL (1) | IL106421A (fr) |
NO (1) | NO301018B1 (fr) |
NZ (1) | NZ248193A (fr) |
ZA (1) | ZA935267B (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
US6129910A (en) * | 1993-06-02 | 2000-10-10 | Geltex Pharmaceuticals, Inc. | Water-insoluble noncrosslinked bile acid sequestrants |
US5900475A (en) * | 1994-06-10 | 1999-05-04 | Geltex Pharmaceuticals, Inc. | Hydrophobic sequestrant for cholesterol depletion |
US5618530A (en) * | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
US5929184A (en) * | 1993-06-02 | 1999-07-27 | Geltex Pharmaceuticals, Inc. | Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants |
US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5414068A (en) * | 1994-01-24 | 1995-05-09 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
DE19520092A1 (de) * | 1995-06-01 | 1996-12-05 | Bayer Ag | Verfahren zur Papierveredlung unter Verwendung von Polyisocyanaten mit anionischen Gruppen |
US6491903B1 (en) | 1996-06-27 | 2002-12-10 | Washington University | Particles comprising amphiphilic copolymers |
DE19633268A1 (de) * | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
US6203785B1 (en) | 1996-12-30 | 2001-03-20 | Geltex Pharmaceuticals, Inc. | Poly(diallylamine)-based bile acid sequestrants |
DE19705992A1 (de) * | 1997-02-17 | 1998-08-20 | Basf Ag | Verfahren zur Herstellung von Carbamateinheiten enthaltenden Polymerisaten und ihre Verwendung |
US5925379A (en) * | 1997-03-27 | 1999-07-20 | Geltex Pharmaceuticals, Inc. | Interpenetrating polymer networks for sequestration of bile acids |
US6423754B1 (en) * | 1997-06-18 | 2002-07-23 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with polyallylamine polymers |
FR2766194A1 (fr) * | 1997-07-21 | 1999-01-22 | Transgene Sa | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique |
FR2766195A1 (fr) * | 1997-07-21 | 1999-01-22 | Transgene Sa | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique |
US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
US6083497A (en) | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
AT409630B (de) * | 2000-12-13 | 2002-09-25 | Dsm Fine Chem Austria Gmbh | Alkylierung von n-bzw. amino- oder ammoniumgruppen haltigen, vernetzten polymeren |
EP1458769B1 (fr) * | 2001-12-21 | 2008-12-31 | Ciba Holding Inc. | Copolymeres de poly(vinyl alcool)-co-poly(n-vinyl formamide) |
EP1456250B1 (fr) | 2001-12-21 | 2009-01-14 | Ciba Holding Inc. | Polymeres poly(vinylalcool)-co-poly(vinylamine) comportant des fractions fonctionnelles |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
JP2008526771A (ja) * | 2004-12-30 | 2008-07-24 | ジェンザイム コーポレーション | 高リン酸血症のための亜鉛含有処置 |
CA2620406A1 (fr) * | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Recepteurs moleculaires polymeriques utilises comme sequestrants du phosphate |
HUE026628T2 (en) | 2005-09-15 | 2016-06-28 | Genzyme Corp | Pouches for amine polymers |
US20090162314A1 (en) * | 2005-11-08 | 2009-06-25 | Huval Chad C | Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia |
JP2009542653A (ja) * | 2006-07-05 | 2009-12-03 | ジェンザイム コーポレーション | リン酸塩過剰血症のための鉄(ii)含有治療剤 |
BR112012021444A2 (pt) | 2010-02-24 | 2016-05-31 | Relypsa Inc | polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas. |
RU2612795C2 (ru) | 2010-02-24 | 2017-03-13 | Релипса, Инк. | Аминосодержащие полимеры для применения в качестве секвестрантов желчных кислот |
MA41202A (fr) | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3558581A (en) * | 1967-10-20 | 1971-01-26 | Hoechst Ag | Process for the manufacture of polyvinylmethylamines |
US4238579A (en) * | 1979-05-18 | 1980-12-09 | Dynapol | Vinylamine aromatic copolymers and salts thereof |
DE3128478A1 (de) * | 1981-07-18 | 1983-02-03 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von linearen, basischen polymerisaten |
DE3213873A1 (de) * | 1982-04-15 | 1983-10-27 | Basf Ag, 6700 Ludwigshafen | Flockungsmittel fuer schlaemme |
FI70230C (fi) * | 1981-07-18 | 1986-09-15 | Basf Ag | Rakkedjiga basiska polymerisat foerfarande foer deras framstaellning och deras anvaendning |
OA08092A (fr) * | 1984-05-11 | 1987-03-31 | Bristol Myers Co | Novel bile sequestrant resin and uses. |
DE3534273A1 (de) * | 1985-09-26 | 1987-04-02 | Basf Ag | Verfahren zur herstellung von vinylamin-einheiten enthaltenden wasserloeslichen copolymerisaten und deren verwendung als nass- und trockenverfestigungsmittel fuer papier |
NL8502882A (nl) * | 1985-10-22 | 1987-05-18 | Stork Friesland Bv | Werkwijze voor de bereiding van een n-vinyl-n-alkilamine (co) polymeer en samengesteld membraan vervaardigd onder toepassing van dit (co) polymeer. |
CA1330684C (fr) * | 1988-04-15 | 1994-07-12 | Robert Krantz Pinschmidt Jr. | Methode pour la preparation de poly(alcool vinylique)-copoly(vinylamide) par un procede a deux etapes |
DE3901527A1 (de) * | 1989-01-20 | 1990-07-26 | Hoechst Ag | Alkylierte polyethyleniminderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel sowie pharmazeutische praeparate |
DE4007312C2 (de) * | 1990-03-08 | 2000-04-27 | Basf Ag | Verfahren zur Herstellung von feinteiligen, wasserlöslichen, Vinylamin-Einheiten enthaltenden Polymerisaten |
-
1993
- 1993-07-15 DK DK93111376.5T patent/DK0580079T3/da active
- 1993-07-15 ES ES93111376T patent/ES2096150T3/es not_active Expired - Lifetime
- 1993-07-15 DE DE59304725T patent/DE59304725D1/de not_active Expired - Fee Related
- 1993-07-15 EP EP93111376A patent/EP0580079B1/fr not_active Expired - Lifetime
- 1993-07-15 AT AT93111376T patent/ATE146193T1/de not_active IP Right Cessation
- 1993-07-20 NZ NZ248193A patent/NZ248193A/en unknown
- 1993-07-20 FI FI933274A patent/FI933274A/fi unknown
- 1993-07-20 IL IL10642193A patent/IL106421A/en not_active IP Right Cessation
- 1993-07-21 ZA ZA935267A patent/ZA935267B/xx unknown
- 1993-07-21 JP JP5179680A patent/JPH06157671A/ja active Pending
- 1993-07-21 AU AU42089/93A patent/AU659562B2/en not_active Ceased
- 1993-07-21 CA CA002101010A patent/CA2101010A1/fr not_active Abandoned
- 1993-07-21 KR KR1019930013756A patent/KR940005692A/ko not_active Application Discontinuation
- 1993-07-21 NO NO932635A patent/NO301018B1/no not_active IP Right Cessation
- 1993-07-21 US US08/095,624 patent/US5428112A/en not_active Expired - Lifetime
-
1995
- 1995-05-30 US US08/452,797 patent/US5631326A/en not_active Expired - Lifetime
-
1996
- 1996-12-20 GR GR960403573T patent/GR3022135T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL106421A (en) | 1996-11-14 |
EP0580079A1 (fr) | 1994-01-26 |
DE59304725D1 (de) | 1997-01-23 |
NO932635D0 (no) | 1993-07-21 |
GR3022135T3 (en) | 1997-03-31 |
NO932635L (no) | 1994-01-24 |
FI933274A0 (fi) | 1993-07-20 |
ES2096150T3 (es) | 1997-03-01 |
US5631326A (en) | 1997-05-20 |
ATE146193T1 (de) | 1996-12-15 |
US5428112A (en) | 1995-06-27 |
FI933274A (fi) | 1994-01-23 |
DK0580079T3 (da) | 1997-06-30 |
AU659562B2 (en) | 1995-05-18 |
NZ248193A (en) | 1995-04-27 |
ZA935267B (en) | 1994-04-18 |
JPH06157671A (ja) | 1994-06-07 |
EP0580079B1 (fr) | 1996-12-11 |
CA2101010A1 (fr) | 1994-01-23 |
IL106421A0 (en) | 1993-11-15 |
KR940005692A (ko) | 1994-03-22 |
AU4208993A (en) | 1994-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO301018B1 (no) | Tverrbundne nitrogeninneholdende vinylkopolymerer, fremgangsmåte for fremstilling av dem samt anvendelse av slike forbindelser | |
AU673479B2 (en) | Polyvinylamine derivatives having hydrophilic centers, processes for their preparation and the use of the compounds as a medicament, active compound carrier and foodstuff auxiliary | |
JP6247740B2 (ja) | 胆汁酸捕捉剤として使用するための架橋されたポリビニルアミン、ポリアリルアミンおよびポリエチレンイミン | |
JP4326143B2 (ja) | 毒素結合剤としてのカチオン性ポリマー | |
CA2117371C (fr) | Medicament abaissant le taux de cholesterol | |
EP3130343B1 (fr) | Polyimidazoles à utiliser en tant qu'agents séquestrants des acides biliaires | |
JPH06502391A (ja) | ポリマー性薬剤送達システム | |
KR20000069826A (ko) | 폴리(디알릴아민)계 담즙산 제거제 | |
JPH10501264A (ja) | 患者から胆汁酸塩を除去するための架橋ポリマー | |
US20100189679A1 (en) | Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes | |
JP2017190464A (ja) | 胆汁酸捕捉剤として使用するためのアミンポリマー | |
JP2004535384A (ja) | 血清グルコースの減少方法 | |
MXPA02000492A (es) | Polimeros enlazantes de grasas, opcionalmente combinados con inhibidores de lipasas. | |
JPH01316324A (ja) | コレステロール低下剤 | |
JPH0448778B2 (fr) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN JANUARY 2001 |